Reprint

Biomarkers of Tumor Metastasis and Invasiveness

Edited by
January 2024
306 pages
  • ISBN978-3-03928-590-7 (Hardback)
  • ISBN978-3-0365-9999-1 (PDF)

This book is a reprint of the Special Issue Biomarkers of Tumor Metastasis and Invasiveness that was published in

Biology & Life Sciences
Medicine & Pharmacology
Summary

The molecular characterization of tumors, investigated particularly through proteogenomic analyses, has led to a revolution in cancer research. Over the last decade, the development of quantitative proteomics, together with other major technological breakthroughs, have identified candidate biomarkers for diagnosis, prognosis, and drug efficacy/resistance follow-up. These improvements have allowed researchers to explore the capability of cancer cells to invade, metastasize, and finally, destroy normal tissues and organs. In parallel, new hypotheses have been formulated, and the means cancer cells use to exploit their surrounding environment have begun to be deciphered, leading to new therapeutic approaches. This Special Issue covers all these aspects, revealing new, recent insights on the molecular networks controlling the tumor invasiveness process; dynamic interactions between cancer cells; and the host stroma, stemness and epithelial-to-mesenchymal transition, as well as the links between inflammation and tumor metastasis. The scope is extended to studies on all cancer histological types (original research articles and reviews) conducted on experimental tumor models, tumor samples, and/or biofluids from patients with cancer.

Format
  • Hardback
License and Copyright
© 2022 by the authors; CC BY-NC-ND license
Keywords
SOX9; pancreatic cancer; plasticity; metastasis; EMT; chemoresistance; mitochondrial DNA; tumor progression; metastasis; immune escape; ADAM; biomarker; gastrointestinal tumours; non-small cell lung cancer; adjuvant chemotherapy; biomarker; actinin-4; metastatic ability; non-small cell lung cancer; serum tumor markers; tumor metastasis; tumor stage; prediction; MAPK15; EP3; p50; LUAD; metastasis; CCR7; CCL19; extrahepatic cholangiocarcinoma; epithelial–mesenchymal transition; tumor budding; defense response; osteosarcoma; prognosis; metastasis; immune; therapy; Glioblastoma; sortilin; cancer biomarkers; cancer therapeutic targets; gastric cancer; surgery; peripheral lymphocyte subsets; prognostic nutritional index; prognostic factor; endometrial cancer; advanced stage; outcome; high-grade; CA125; oral cancer; NLRP3; metastasis; lymph node; spleen; lung; malignant mesothelioma; metabolism; mitochondria; long-chain specific acyl-CoA dehydrogenase; fatty acid β-oxidation; biomarker; VIP; ZEB1; cancer; EMT; gastrointestinal cancers; multiple myeloma; extramedullary multiple myeloma; extramedullary disease; proteomics; mass spectrometry; clinical proteomics; metabolomics; exosomes; prostasin; matriptase; protease activation cascade; gelatinase activity; lymphoma; IMP3; lip cancer; squamous cell carcinoma; ear cancer; skin cancer; HNSCC; n/a

Related Books

February 2021

New Prognostic and Predictive Markers in Cancer Progression

Biology & Life Sciences
...
September 2019

Cancer Metabolomics 2018

Biology & Life Sciences
September 2019

Cancer Biomarkers and Targets in Digestive Organs

Medicine & Pharmacology
August 2022

Novel Biomarkers of Gastrointestinal Cancer

Medicine & Pharmacology
March 2023

Angiogenesis in Cancers

Biology & Life Sciences
...